Blog
RSS FeedPosted by Michael Wonder on 16 Jun 2021
Medicare must study unproven, expensive Alzheimer’s drug
15 June 2021 - Tax payers and patients cannot afford to pay a high price for a treatment not known to ...
Posted by Michael Wonder on 15 Jun 2021
Health care funding decisions and real world benefits: reducing bias by matching untreated patients
14 June 2021 - Governments and health insurers often make funding decisions based on health gains from randomised controlled trials. ...
Posted by Michael Wonder on 10 Jun 2021
Biogen’s new Alzheimer’s drug could cost Medicare billions of dollars a year, report finds
10 June 2021 - “If 1 million Medicare beneficiaries receive Aduhelm, which may even be on the low end of Biogen’s ...
Posted by Michael Wonder on 09 Jun 2021
Alzheimer’s drug is bonanza for Biogen, most likely at taxpayer expense
8 June 2021 - The FDA’s decision on Monday to approve a new Alzheimer’s medication over the fierce objections of ...
Posted by Michael Wonder on 06 Jun 2021
Patients set to pay thousands more as rebates cut in raft of radical Medicare changes
6 June 2021 - A chaotic attempt to modernise the 38 year old Medicare system could see patients hit with higher ...
Posted by Michael Wonder on 16 May 2021
Modernising Medicare coverage pathways for prescription digital therapeutics
13 May 2021 - Outpatient visit restrictions imposed in early 2020 due to COVID-19 increased demand for effective virtual health care ...
Posted by Michael Wonder on 12 May 2021
Allow Medicare to negotiate on behalf of patients to lower drug prices
12 May 2021 - President Biden’s speech announcing his American Families Plan reaffirmed his strong support for legislation to lower ...
Posted by Michael Wonder on 07 May 2021
Medicare beneficiaries can't wait for lower drug prices
7 May 2021 - Medicare beneficiaries have been among the hardest-hit populations by the pandemic for the last 13 months — ...
Posted by Michael Wonder on 07 May 2021
Avelumab not recommended as a maintenance treatment of urothelial cancer after platinum-based chemotherapy
7 May 2021 - NICE has issued draft guidance which does not recommend avelumab for maintenance treatment of locally advanced or ...
Posted by Michael Wonder on 06 Apr 2021
United Therapeutics announces FDA approval and launch of Tyvaso for the treatment of pulmonary hypertension associated with interstitial lung disease
1 April 2021 - First and only approved therapy in the United States for patients with PH-ILD, a serious, life-threatening ...
Posted by Michael Wonder on 15 Mar 2021
Update on finalisation of MCIT rule to provide national Medicare coverage for FDA breakthrough devices and diagnostics
15 March 2021 - Renalytix AI provides an update on the establishment of the Medicare Coverage of Innovative Technology (MCIT) ...
Posted by Michael Wonder on 11 Mar 2021
Medicare’s new device coverage pathway — breakthrough or breakdown?
10 March 2021 - CMS recently finalised a rule that could substantially alter Medicare coverage decisions for certain new medical devices. ...
Posted by Michael Wonder on 09 Mar 2021
Sun Pharma announces Drizalma Sprinkle (duloxetine delayed release capsules) is now covered by most Medicare Part D plans
9 March 2021 - Coverage for novel formulation of duloxetine now offered to 91% of lives in top 10 Medicare Part ...
Posted by Michael Wonder on 21 Jan 2021
With a new president and a new Congress, it's time for Medicare drug price negotiation
20 January 2021 - Since passage of the Medicare Modernization Act in 2003, which prohibited Medicare from negotiating prescription drug prices, ...
Posted by Michael Wonder on 18 Jan 2021
Changes to Medicare Advantage and Part D will provide better coverage, more access and improved transparency for Medicare beneficiaries
15 January 2021 - Today, the CMS issued a final rule that further advances the agency’s efforts to strengthen and modernise ...